Luminex eyes FDA approval for HSV 1&2 tests; Biocept rolls out BRAF mutation test;

> Luminex ($LMNX) submitted its 510(k) applications to the FDA for its HSV 1&2 test. Statement

> The companion diagnostics market is expected to reach $5.6 billion in 2019, according to a new report. Release

> San Diego, CA-based Biocept ($BIOC) launched its test for BRAF mutations in patients with melanoma. More

> Curetis is kicking off the next phase in a trial for a second-generation version of its diagnostic system for lower respiratory tract (LRT) infections. Statement

> Progenetics inked a deal with OncoDNA to distribute the company's products in Israel. Story (reg. req.)

And Finally… A new study comparing Ebola diagnostics approved for emergency use found that a test from bioMérieux's BioFire Diagnostics unit was faster and easier to use than other products. Abstract